Search by Drug Name or NDC
NDC 17856-0595-04 Sodium Citrate and Citric Acid 334; 500 mg/5mL; mg/5mL Details
Sodium Citrate and Citric Acid 334; 500 mg/5mL; mg/5mL
Sodium Citrate and Citric Acid is a ORAL SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ATLANTIC BIOLOGICALS CORP.. The primary component is ANHYDROUS CITRIC ACID; SODIUM CITRATE.
Product Information
NDC | 17856-0595 |
---|---|
Product ID | 17856-0595_c24a3a80-1e82-409b-bb4d-8e5e548fc00c |
Associated GPIs | |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | Sodium Citrate and Citric Acid |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | SODIUM CITRATE and CITRIC ACID MONOHYDRATE |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | SOLUTION |
Route | ORAL |
Active Ingredient Strength | 334; 500 |
Active Ingredient Units | mg/5mL; mg/5mL |
Substance Name | ANHYDROUS CITRIC ACID; SODIUM CITRATE |
Labeler Name | ATLANTIC BIOLOGICALS CORP. |
Pharmaceutical Class | Acidifying Activity [MoA], Acidifying Activity [MoA], Anti-coagulant [EPC], Anti-coagulant [EPC], Calcium Chelating Activity [MoA], Calcium Chelating Activity [MoA], Calculi Dissolution Agent [EPC], Calculi Dissolution Agent [EPC], Decreased Coagulation F |
DEA Schedule | n/a |
Marketing Category | UNAPPROVED DRUG OTHER |
Application Number | n/a |
Listing Certified Through | 2023-12-31 |
Package
Package Images

NDC 17856-0595-04 (17856059504)
NDC Package Code | 17856-0595-4 |
---|---|
Billing NDC | 17856059504 |
Package | 1 CASE in 1 CUP, UNIT-DOSE (17856-0595-4) / 50 CUP in 1 CASE (17856-0595-3) / 30 mL in 1 CUP |
Marketing Start Date | 2022-09-02 |
NDC Exclude Flag | N |
Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL 42d837ae-2578-46df-92d2-24774964aaad Details
DESCRIPTION
Sodium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting systemic alkalizer containing sodium citrate and citric acid in a sugar-free base. It is a nonparticulate neutralizing buffer.
Sodium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):
SODIUM CITRATE Dihydrate 500 mg (0.34 Molar)
CITRIC ACID Monohydrate 334 mg (0.32 Molar)
Each mL contains 1 mEq sodium ion and is equivalent to 1 mEq bicarbonate (HCO3).
INACTIVE INGREDIENTS: Flavoring, polyethylene glycol, propylene glycol, purified water, sodium benzoate, and sorbitol solution.
CLINICAL PHARMACOLOGY
Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.
INDICATIONS AND USAGE
Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.
Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.
PRECAUTIONS
Sodium Citrate and Citric Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy. Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.
ADVERSE REACTIONS
Sodium Citrate and Citric Acid Oral Solution USP is generally well tolerated, without any unpleasant side effects, when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.
OVERDOSAGE
DOSAGE AND ADMINISTRATION
For Systemic Alkalization
As a neutralizing buffer
STORAGE:
SPL UNCLASSIFIED SECTION
INGREDIENTS AND APPEARANCE
SODIUM CITRATE AND CITRIC ACID
sodium citrate and citric acid monohydrate solution |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
Labeler - ATLANTIC BIOLOGICALS CORP. (047437707) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
ATLANTIC BIOLOGICALS CORP. | 047437707 | REPACK(17856-0595) |